RegCell is developing immunotherapy solutions that utilize immune modulation techniques to target autoimmune diseases and cancer. The company aims to provide effective treatment options that enhance patient outcomes by addressing the underlying mechanisms of these conditions.
Funding
$18.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Autoimmune diseases and cancer present significant challenges due to their complex underlying mechanisms and the limitations of existing treatment options. Current therapies often fail to provide long-term remission or have significant side effects, highlighting the need for more targeted and effective approaches.
Solution
RegCell is developing novel immunotherapies that leverage immune modulation to treat autoimmune diseases and cancer. Their approach focuses on precisely regulating the immune system to restore balance in autoimmune disorders and enhance anti-tumor responses in cancer. By targeting the fundamental mechanisms driving these conditions, RegCell aims to provide therapies that offer improved efficacy and reduced toxicity compared to conventional treatments. The company's research is based on innovative insights into immune regulation and its potential for therapeutic intervention.
Target Audience
The primary target audience includes patients suffering from autoimmune diseases and various forms of cancer, as well as healthcare providers seeking innovative treatment options for these conditions.
Features
- Utilizes immune modulation techniques to selectively target disease-causing immune cells.
- Focuses on restoring immune homeostasis in autoimmune diseases.
- Enhances the body's natural ability to fight cancer by modulating the immune response.